Zijing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zijing Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Brenda Salumbides
Center for Uro-Oncology Research Excellence, Cedars-Sinai Cancer, Los Angeles, California
11 shared publications - Catherine S. Grasso
Center for Uro-Oncology Research Excellence, Cedars-Sinai Cancer, Los Angeles, California
11 shared publications - Dolores Di Vizio
Department of Urology Cedars‐Sinai Health Sciences University Los Angeles California USA
11 shared publications - Edwin Melencio Posadas
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
11 shared publications - Howard Mark Sandler
Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
11 shared publications - Hsian-Rong Tseng
California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology
11 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 1. A general workflow and method of NanoVelcro CTC Enumeration Assay.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 1. A general workflow and method of NanoVelcro CTC Enumeration Assay.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 5. Western-blot of EMD in 22Rv1 and C4-2B EMD-knockdown cells by shRNA.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 5. Western-blot of EMD in 22Rv1 and C4-2B EMD-knockdown cells by shRNA.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 1. Real-time PCR Oligonucleotide Sequence.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 1. Real-time PCR Oligonucleotide Sequence.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 4. Western-blot of EMD in 22Rv1 EMD-knockdown cells by siRNA.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 4. Western-blot of EMD in 22Rv1 EMD-knockdown cells by siRNA.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 2. vsnCTCs are associated with poorer clinical outcomes in advanced prostate cancer.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 2. vsnCTCs are associated with poorer clinical outcomes in advanced prostate cancer.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 2. Univariate and multivariable Cox regression analyses.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 2. Univariate and multivariable Cox regression analyses.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 6. Cell Viability of 22Rv1 EMD knockdown cells by shRNA after 5 days treatment of 10 µM abiraterone acetate A), and 5 µM enzalutamide (ENZA) B).
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 6. Cell Viability of 22Rv1 EMD knockdown cells by shRNA after 5 days treatment of 10 µM abiraterone acetate A), and 5 µM enzalutamide (ENZA) B).
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 3. P-spline curve comparing CTC number and hazard ratio for overall survival.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 3. P-spline curve comparing CTC number and hazard ratio for overall survival.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 4. Univariate and multivariable Cox regression analyses for patients with detectable CTCs adjusted for minimum nuclear size.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 4. Univariate and multivariable Cox regression analyses for patients with detectable CTCs adjusted for minimum nuclear size.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 3. All subsequent treatments after vsnCTC assessment.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 3. All subsequent treatments after vsnCTC assessment.